%0 Journal Article
%T Percutaneous Dilatational Tracheostomy in Patients with Hematologic Cancers: A Retrospective Cohort Analysis of Safety and Clinical Outcomes
%A Marco L. De Santis
%A Lucia F. Romano
%A Paolo Ricci
%J Bulletin of Pioneering Researches of Medical and Clinical Science
%@ 3006-2659
%D 2021
%V 1
%N 1
%R 10.51847/F5ZLg8c1rA
%P 94-102
%X Critically ill patients with hematologic malignancies (HM) frequently present with blood-related complications such as thrombocytopenia, coagulopathy, anemia, and leukopenia, which can considerably elevate the risk of both procedural and post-procedural adverse events. This study investigates the safety profile and clinical outcomes of percutaneous dilatational tracheostomy (PDT) in this high-risk population. We conducted a retrospective cohort study of HM patients who underwent PDT at a tertiary academic hospital from 2012 to 2023. The primary endpoint was the occurrence of bleeding complications within the first 7 days post-procedure. Secondary outcomes included procedure-related mortality and overall mortality at 7 days, thirty days, and one year. Propensity score matching was employed to adjust for baseline differences and allow accurate comparison with non-HM patients.

Among 1,627 patients included, 65 (4 percent) had HM. Patients with HM exhibited a higher Charlson comorbidity index and a markedly greater prevalence of thrombocytopenia (platelets 
%U https://bprmcs.com/article/percutaneous-dilatational-tracheostomy-in-patients-with-hematologic-cancers-a-retrospective-cohort-qkhj5pg9ayzoosl